Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2024 | $166.00 | Neutral | BofA Securities |
| 11/15/2024 | $190.00 | Outperform | Wolfe Research |
| 7/23/2024 | $160.00 → $150.00 | Outperform → Neutral | Daiwa Securities |
| 5/30/2024 | $160.00 | Neutral | Goldman |
| 4/18/2024 | $170.00 | Hold → Buy | HSBC Securities |
| 12/13/2023 | $170.00 → $163.00 | Overweight → Equal Weight | Wells Fargo |
| 12/1/2023 | $167.00 → $180.00 | Neutral → Buy | UBS |
| 10/5/2023 | $178.00 | Outperform | RBC Capital Mkts |
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines
Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are effective May 1, 2025, and Mr. Snellgrove as well as Ms. Moore, will continue to report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph Wolk. "Today's announcement reflects the deep bench of talent within Johnson & Johnson as well
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
New social impact platform J&J CareCommunity aims to collaboratively help address global nursing challenges Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the world. These efforts are part of J&J CareCommunity, a new social impact platform that focuses the resources and expertise of J&J and J&J Foundation to support nurses at every step of their career journey and strengthen health systems worldwide. The expansion aims to help address the global shortfall of nurses, which will reach approximately 4.5 million by 2030, driven in part by burnout and low morale, contributing to a signifi
Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week (DDW) 2025. Data from the QUASAR LTE
TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn's disease SAN DIEGO, May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC). The ASTRO Week 24 data build on the Week 12 SC induction data that showed statistically significant and clinically meaningful improvements compared to placebo acros
BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00
Wolfe Research initiated coverage of Johnson & Johnson with a rating of Outperform and set a new price target of $190.00
Daiwa Securities downgraded Johnson & Johnson from Outperform to Neutral and set a new price target of $150.00 from $160.00 previously
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)
8-K - JOHNSON & JOHNSON (0000200406) (Filer)
10-Q - JOHNSON & JOHNSON (0000200406) (Filer)
Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the close of business on May 27, 2025. The ex-dividend date is May 27, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, trea
2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn's disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the
Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution Today, the U.S. Bankruptcy Court for the Southern District of Texas denied the request by Johnson & Johnson (NYSE:JNJ) (the "Company") subsidiary Red River Talc LLC ("Red River") to confirm its proposed prepackaged bankruptcy plan—notwithstanding that it offered one of the largest settlements ever proposed in a mass tort bankruptcy and was supported by the overwhelming majority of claimants. Rather than pursue a protracted appeal, the Company will return to the tort system to litigate and defeat these merit
For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin
For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not
For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione